Merck in supply agreement with U.S. government for its COVID-19 treatment

[December 23, 2020]  (Reuters) - Merck & Co said on Wednesday it will supply about 60,000-100,000 doses of its COVID-19 treatment to the U.S. government for up to about $356 million.

The agreement will help support advanced development and large-scale manufacturing of Merck's investigational therapeutic MK-7110 to treat hospitalized patients with severe or critical COVID-19, The U.S. Department of the Health and Human Services said.

(Reporting by Ankur Banerjee in Bengaluru; Editing by Bernard Orr)

[© 2020 Thomson Reuters. All rights reserved.]

Copyright 2020 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.